Common drug interactions and reactions

• A drug interaction is any change in the effect of a drug caused by another drug, food, drink, supplement, or disease. Some are predictable from pharmacokinetics or pharmacodynamics; others appear only in particular patients.
• Metabolic interactions usually involve competition for cytochrome P450 (CYP) enzymes in the liver: an inhibitor slows clearance and can cause toxicity, while an inducer speeds clearance and can cause therapeutic failure.
• Protein-binding displacement and additive pharmacodynamic effects (bleeding, QT prolongation, sedation, serotonin excess) are the other two large mechanisms, and they can be fatal before they are obvious.
• A severe cutaneous reaction such as Stevens-Johnson syndrome or toxic epidermal necrolysis, drug-induced lupus, a blood dyscrasia, or rising liver or renal tests can all be drug-induced and must be linked to the drug by timing and, where possible, by rechallenge avoidance.
• Most adverse drug reactions (ADRs) are preventable: a full medication and allergy history, careful documentation, avoidance of interacting pairs, and prompt reporting of serious events catch the majority before they harm patients.

By the end of this page you should be able to:

1. Explain the three main mechanisms of drug interaction: CYP450 induction and inhibition, protein-binding displacement, and additive pharmacodynamic effects, with named example pairs.
2. Predict risk for victim drugs such as warfarin, combined oral contraceptives, statins, calcineurin inhibitors and tacrolimus, amiodarone, and theophylline, using a short list of common inducers and inhibitors.
3. Recognise serotonin syndrome and drug-induced QT prolongation, state the drug classes most often involved, and outline immediate management.
4. Classify a severe reaction correctly and connect it to its likely trigger (Stevens-Johnson syndrome and toxic epidermal necrolysis, drug-induced lupus, photosensitivity, gynaecomastia, blood dyscrasias, hepatotoxicity, nephrotoxicity).
5. Distinguish the four types of hypersensitivity reaction, with mechanism and typical onset, and give examples of drugs that cause each.
6. Explain the difference between Type A and Type B ADRs, and describe concrete steps for preventing, identifying, and reporting ADRs, including to MedWatch.
7. Use a simple bedside algorithm: stop the suspected drug, assess severity, support organs, give a targeted antidote where one exists, and document and report.

An interaction is not an error in itself; it is a change in a drug's effect because of another substance or condition. Some interactions are exploited deliberately, such as ritonavir boosting other protease inhibitors. Many are harmful. They can make a drug fail (enzyme induction lowering a contraceptive or an immunosuppressant) or make it toxic (inhibition raising warfarin or a statin). Remember that disease states such as cirrhosis, renal impairment, and the inflammatory state can change protein binding, enzyme expression, and excretion, so the same prescription behaves differently in different patients. ^{[1] [2]}

Cytochrome P450 (CYP) enzymes are mixed-function oxidases, mainly in the liver but also in the intestinal wall, that make lipophilic drugs more water-soluble for excretion. Six isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5) account for an estimated 80% to 90% of enzymatic drug metabolism. ^[1] CYP3A4/5 alone participates in the metabolism of about 30% of clinically used drugs, and CYP2D6 in about 20%. ^[1]

Two ideas follow directly.

• Induction increases enzyme activity, lowers substrate concentrations, and can cause treatment failure. Common inducers are rifampin, carbamazepine, phenytoin, phenobarbital, griseofulvin, St John's wort, ethanol, tobacco, and nicotine-containing products.
• Inhibition decreases enzyme activity, raises substrate concentrations, and can cause accumulation and toxicity. Common inhibitors include macrolide antibiotics, azole antifungals, ritonavir, amiodarone, fluoxetine, paroxetine, ciprofloxacin, cimetidine, and grapefruit juice.

Induction usually takes days to reach full effect because new enzyme is made, whereas inhibition can occur within hours. Prodrugs are a special case: enzyme induction can increase an active metabolite (for example codeine to morphine via CYP2D6) and cause opioid toxicity, and enzyme inhibition can abolish the effect of the prodrug. ^[1]

The following is a teaching summary compiled from the two StatPearls sources. It is not exhaustive; check a current interaction database before prescribing for a specific patient. ^{[1] [2]}

People inherit different CYP activity. Genotypes are grouped as poor, intermediate, extensive (normal), or ultrarapid metabolisers. Poor CYP2D6 metabolisers get little benefit from codeine because they make almost no morphine; ultrarapid metabolisers can make a dangerous amount of morphine from standard doses. ^[1] Rifampin, phenytoin, and carbamazepine are strong inducers that patients with epilepsy or tuberculosis may take for months, so think of them every time an unusual treatment failure occurs.

Many drugs bind to plasma proteins, mostly albumin, and only the free, unbound fraction reaches the tissues and causes an effect. When two highly bound drugs compete for the same binding site, the free fraction of one or both rises. This is usually clinically important only for drugs that are more than 90% protein bound, and it is amplified in hypoalbuminaemia (malnutrition, inflammation, chronic liver or renal disease) where there is less binding capacity overall. ^[2]

Aspirin and warfarin compete for the same plasma protein binding site: giving both can increase unbound drug and potentiate effects, with bleeding risk. ^[2] Any highly protein-bound drug (phenytoin, valproate, thyroxine, several NSAIDs) is more "active" in hypoalbuminaemia even when the total level looks normal; this is why free phenytoin levels matter in critical illness.

These interactions happen at the receptor or organ level rather than in the liver. Two drugs amplify the same physiological effect. Examples include additive bleeding from anticoagulants and antiplatelets; additive hypotension from antihypertensives, nitrates, and phosphodiesterase inhibitors; additive sedation from benzodiazepines, opioids, and alcohol; and additive anticholinergic burden from many common drugs in older adults. QT prolongation and serotonin syndrome are the two best-known lethal examples and deserve their own sections below. ^{[2] [6]}

Serotonin (5-hydroxytryptamine) is a monoamine neurotransmitter. Most of the body's serotonin (about 90%) is made by intestinal enterochromaffin cells, about 8% is in platelets, and about 2% is in the central nervous system. ^[3] Serotonin syndrome results from excessive serotonergic activity anywhere in that system, and it is probably under-recognised in its mild form. ^[3]

Both single-agent therapy and combinations can precipitate it. MAO inhibitors (monoamine oxidase inhibitors) inhibit serotonin breakdown and are associated with the most severe cases. CYP interactions matter: serotonergic drugs metabolised by CYP2D6 and CYP3A4 can accumulate when a non-serotonergic CYP inhibitor (ciprofloxacin, fluconazole) is added, raising serotonergic drug concentrations. ^[3]

Symptoms are sudden and present within about 6 to 24 hours of a new drug, dose change, or interaction. ^[3] The clinical triad is:

• mental state change (agitation, confusion, hypomania, delirium),
• autonomic dysfunction (tachycardia, hypertension then hypotension, hyperthermia, diaphoresis, mydriasis, hyperactive bowel sounds, diarrhoea),
• neuromuscular hyperactivity (tremor, hyperreflexia, ankle clonus, ocular clonus, hypertonia, seizures).

Lower-limb findings are often most obvious. ^[3]

The Hunter Toxicity Criteria are the most accurate clinical decision rule, with about 84% sensitivity and about 97% specificity: recent serotonergic exposure plus one of spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with temperature over 38 C together with ocular or inducible clonus. ^[3]

Management: stop all serotonergic drugs; supportive care with intravenous fluids, oxygen, and cardiac monitoring; sedation with benzodiazepines (no serotonergic or anticholinergic activity); short-acting agents such as esmolol or nicardipine for autonomic instability; external cooling for high temperatures; and, in refractory cases, cyproheptadine 12 mg initially, then 2 mg every 2 hours until response. ^[3] Antipyretics such as paracetamol do not help because the heat comes from muscle activity rather than a raised set point. ^[3] Prevention rests on avoiding multiple serotonergic agents where possible, checking CYP interactions when adding any drug, and warning patients to seek help promptly for the symptom cluster. ^[3]

QT prolongation reflects delayed ventricular repolarisation and predisposes to torsades de pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation. A normal QTc is 440 ms or less in men and 460 ms or less in women; prolongation past 500 ms carries increased risk of torsades. ^[5] The common mechanism is blockade of the human ether-a-go-go-related gene (hERG) potassium channels, reducing repolarising potassium current. ^[5]

Common QT-prolonging drug classes are:

• antiarrhythmics (amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide),
• antibiotics (macrolides, fluoroquinolones),
• antipsychotics (haloperidol, droperidol, thioridazine, ziprasidone, risperidone, quetiapine, olanzapine),
• antidepressants (amitriptyline, imipramine, citalopram),
• others (methadone, ondansetron, sumatriptan, cisapride).

Risk is amplified by unrecognised CYP inhibition: a CYP3A4 substrate that also prolongs QT (such as cisapride or terfenadine-like drugs) is far more dangerous alongside an inhibitor such as clarithromycin or grapefruit juice. ^[5]

Risk factors and monitoring: electrolyte disturbances (hypokalaemia, hypomagnesaemia, hypocalcaemia), female sex, older age, congenital long QT, bradyarrhythmias, heart disease, diabetes, and drugs causing diarrhoea or diuretic use. ^[5] Baseline and follow-up ECGs are warranted with significant risk or when combining QT-prolonging agents. Avoid combining QT-prolonging drugs; replete potassium, magnesium, and calcium before and during therapy. Treat torsades with magnesium sulfate, correct electrolytes, and review offending agents; amiodarone usually should not be used because it also prolongs QT. ^[5]

These are severe, T-cell-mediated type IV (delayed) hypersensitivity reactions with keratinocyte apoptosis, mucosal necrosis, and widespread epidermal detachment. They are rare (1 to 5 cases per million people per year) but are the prototype of a severe drug reaction, with mortality up to 34% to 50% and higher mortality with larger body surface area involvement. ^[4] Classification by detached body surface area: SJS less than 10%, overlap 10% to 30%, TEN greater than 30%. ^[4]

Common culprits are antiepileptics (lamotrigine, carbamazepine, phenytoin, valproic acid, phenobarbital), allopurinol, antibiotics (trimethoprim-sulfamethoxazole, aminopenicillins, cephalosporins, tetracyclines), nevirapine, NSAIDs, and immune checkpoint inhibitors (nivolumab, pembrolizumab). ^[4] Most cases occur 4 to 28 days after the first dose. Prodrome is flu-like, followed by painful mucocutaneous erosions with a positive Nikolsky sign. Mucosal involvement is present in about 90% of patients and precedes the skin eruption by 1 to 3 days. ^[4]

Key management is immediate withdrawal of all suspected drugs, urgent burn or intensive care transfer, aseptic wound care, fluid resuscitation, infection surveillance, and nutritional support (20 to 25 kcal per kg per day); supportive care is the backbone, as no specific therapy has consistent trial evidence. ^[4] HLA-B*1502 screening before carbamazepine in Han Chinese and some other Asian populations reduces the risk of carbamazepine-induced SJS/TEN. ^[4]

Lupus-like disease can develop after exposure to isoniazid, phenytoin, procainamide, or hydralazine. It typically presents with arthralgia, serositis, and positive antinuclear antibodies; skin and renal involvement are less common than in idiopathic systemic lupus erythematosus, and it usually resolves after the causative drug is stopped. ^[6] Other drugs in the same ADR source cause IgA bullous dermatosis (vancomycin, ceftriaxone) and pemphigus-like disease (penicillamine). ^[6]

Drug photosensitivity is a dose-dependent, UV-triggered skin reaction (phototoxicity), listed in the ADR source as a classic example of a Type A side effect (doxycycline). Other commonly implicated drugs are tetracyclines, fluoroquinolones, amiodarone, thiazides, NSAIDs, and psoralens. Prevention is sun avoidance, protective clothing, broad-spectrum sunscreen, and review of the medication list. ^[6]

Gynaecomastia can be drug-related through hormonal mechanisms (anti-androgens, spironolactone, cimetidine, finasteride, risperidone, oestrogens, digoxin) and, as the CYP source notes, through altered steroid hormone metabolism in cirrhosis, giving gynaecomastia and spider naevi. ^[1] Any new breast tissue in a man warrants a review for drugs, liver disease, and testicular or adrenal pathology.

Drug-related blood dyscrasias include:

• drug-induced haemolytic anaemia: cephalosporins, penicillin (Type II hypersensitivity);
• drug-induced thrombocytopenia: heparin, apixaban, quinidine, sulfonamides;
• drug-induced neutropenia or agranulocytosis: propylthiouracil, flecainide; and
• idiosyncratic reactions such as dapsone-induced haemolysis in G6PD deficiency. ^[6]

Clozapine is a clinically important cause of agranulocytosis in practice although not listed in the cited sources; monitoring protocols should follow local guidelines. Idiosyncratic reactions are dose-independent and not predicted by pharmacology. ^[6] Any unexplained cytopenia in a patient on drugs should prompt a drug review and, where appropriate, a withdrawal challenge arranged by the prescribing team.

Drug-related hepatotoxicity is a major cause of liver injury. Type A examples include liver failure after paracetamol (acetaminophen) overdose, from N-acetyl-p-benzoquinone imine accumulation when glutathione is depleted. ^{[6] [1]} Dose-independent idiosyncratic liver injury occurs with many drugs (antituberculous drugs, antiepileptics, antibiotics, NSAIDs). Drugs metabolised by CYP2E1 such as paracetamol, theophylline, and verapamil are worth knowing. ^[1] CYP inducers (isoniazid, ethanol, tobacco) increase the formation of reactive metabolites and raise hepatotoxicity risk. Monitor liver function tests and educate patients about maximum daily paracetamol doses and the dangers of accidental duplicate dosing.

Aminoglycoside therapy is a classic example of nephrotoxicity as a Type A side effect; tubular injury is dose and duration dependent. ^[6] Elderly patients, pre-existing renal disease, dehydration, and concurrent NSAIDs or vancomycin magnify the risk. Dose adjustment by renal function, drug-level monitoring where available, and hydration are the practical protections. Warfarin overdose and other agents also present with renal injury in severe cases. ^[6]

Adverse drug reactions are usefully split into two families.

• Type A reactions are predictable from the pharmacology of the drug, are dose-dependent, and account for 85% to 90% of ADRs. Subtypes include overdose (warfarin bleeding, paracetamol liver failure, opioid respiratory depression), side effects (NSAID gastritis, aminoglycoside nephrotoxicity, antibiotic diarrhoea, phototoxicity from doxycycline), drug-drug interactions, and secondary effects such as antibacterial superinfection. ^[6]
• Type B reactions are not predicted by the pharmacology of the drug. They include immunologically mediated hypersensitivity and idiosyncratic reactions. ^[6]

Many drug reactions are immunological. The ADR source gives this working scheme, with examples. ^[6]

Hypersensitivity reactions as a whole constitute 6% to 10% of all ADRs. Drug-induced autoimmunity (lupus-like disease after isoniazid, phenytoin, procainamide, hydralazine; bullous IgA disease after vancomycin or ceftriaxone; pemphigus-like disease after penicillamine) and fixed drug eruptions (sulfonamides, anticoagulants) are other important Type B presentations. ^[6]

Pseudoallergic reactions look allergic but are not immunological: they arise from direct inflammatory-cell activation, such as vancomycin flushing syndrome, which can be prevented by slowing the infusion rate. ^[6]

There were over 1.25 million serious adverse events and nearly 175,000 deaths reported to the United States Food and Drug Administration FAERS database in 2022. ^[6] There are 6 emergency department visits for medication harm per 1,000 patients, and about 38% of such visits require hospitalisation. ^[6] In 3 out of every 1,000 hospital admissions, a patient dies due to an ADR. ^[6]

Use open questions, a careful medication history (including over-the-counter drugs, herbal products such as St John's wort, supplements, and alcohol or tobacco), temporal association, and published expected reaction profiles. The Naranjo algorithm (score 9+ definite, 5 to 8 probable, 1 to 4 possible, 0 doubtful) is one of several causality tools; none of them can prove or refute causality on their own. ^[6] Further tests such as tryptase for Type I reactions, skin testing, and patch testing have specific roles. Drug rechallenge is contraindicated after severe reactions such as SJS, TEN, DRESS, or AGEP. ^[6]

• Take and document a detailed allergy and ADR history, with the type, severity, and timing of any prior reaction. ^[6]
• Document known reactions prominently in the record so that all prescribers and pharmacists see them. ^[6]
• Use the right drug for the right indication; avoid antibiotics for viral infections. Tailor doses to age, renal and hepatic function, creatinine clearance, indication, and genetics (for example TPMT, CYP genotype) where available. ^[6]
• Stop the culprit drug promptly at the first sign of a severe reaction; for a mild reaction where the drug is essential, consider dose reduction with close monitoring. ^[6]
• Identify and avoid interacting pairs: drug-drug, drug-food (grapefruit), and drug-disease. A pharmacist is the key team member for this in every setting. ^[6]
• Educate patients about expected side effects, adherence, warning symptoms that need urgent review, and correct epinephrine use for those at risk of anaphylaxis. ^[6]
• Refer patients with suspected or confirmed anaphylaxis to allergy specialists for assessment and desensitisation where appropriate. ^[6]

Prompt reporting is best practice. Special attention goes to events leading to death, life-threatening illness, persistent disability, congenital anomalies, or, for newly marketed drugs, all adverse events. ^[6] In the United States this means MedWatch, the FDA voluntary reporting system. Only about 1% of serious and unexpected ADRs are reported, and underreporting delays detection and intervention. ^[6] Reporting responsibilities and systems differ by country, but the principle is universal: report serious and unexpected reactions without waiting for certainty. Hospital pharmacovigilance systems and national centres play the same role elsewhere. ^[6]

A person on drugs with any of the following needs urgent medical review:

• symptoms within 4 to 28 days of a new drug, or sudden deterioration after adding or changing a drug;
• widespread or painful rash, mucosal involvement, or blisters (SJS/TEN spectrum);
• fever with rash, eosinophilia, or internal-organ involvement (DRESS);
• hypotension, bronchospasm, angioedema, urticaria, or anaphylaxis (Type I);
• confusion, agitation, hyperthermia, tremor, or clonus (serotonin syndrome);
• syncope or palpitations on a QT-prolonging drug;
• rising creatinine, falling counts, or rising liver enzymes after starting a drug;
• new breast tissue, photosensitive rash, arthralgia, or serositis suggesting drug-induced lupus.

• Older adults accumulate anticholinergic and sedative burden and often have renal and hepatic impairment; interactions are more common and more harmful. ^[6]
• Children are excluded from many drug trials; weight-based dosing, renal and hepatic adjustment, and vigilance for drug-induced reactions matter more. ^[2]
• Pregnancy and breastfeeding alter distribution (plasma volume expansion, changes in protein binding) and many drugs cross the placenta or into milk; check current specialist references. ^[2]
• Low-resource settings: an accurate, written drug and allergy history, clinical assessment of timing, an ECG for suspected QT issues, a full blood count and renal and liver function where available, and prompt withdrawal of suspect drugs cost little and save lives. Pharmacist involvement dramatically improves detection of interactions and drug-related problems even in chronic kidney disease. ^{[2] [6]}

Related MedGrasp topics to read alongside this page include the antiarrhythmic and anticoagulant drug topics, serotonin and QT concepts, pharmacokinetics and pharmacodynamics, severe cutaneous adverse reactions, anaemia and blood dyscrasias, and pharmacovigilance and patient safety topics (listed as plain text because the corresponding pages may not all be published in this build).